Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 15045939

[Angiosarcoma].

Toshiaki Saida
View original source ↗Export metadata ↓

Abstract

Angiosarcoma is a malignant neoplasm of endothelial cells. It is a fatal disease because of the high potentiality of hematogeneous metastasis. Although a definitively effective treatment has not yet established, a rational combination of multimodal therapies could prolong the survival time to some extent. In this review, recent advances in the management of this neoplasm are discussed, including those in surgery, radiation, chemotherapy and biotherapy.

Explore related subjects

Antineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyDiagnosis, DifferentialFemaleHemangiosarcomaHumansMalePrognosisRadiotherapy DosageSkin NeoplasmsEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Toshiaki Saida. 2004. [Angiosarcoma].. https://pubmed.ncbi.nlm.nih.gov/15045939/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Mucoepidermoid carcinoma of the parotid gland in a child previously treated for acute lymphoblastic leukemia.

Occurrence of second cancers is a major concern for the care of children cured of cancer. Children treated for acute lymphoblastic leukemia (ALL) have an increased risk for developing mucoepidermoid carcinomas (MEC) of the parotid gland. The latent period ranges from 5 to 16 years. A 3-year-old boy presented with pre-B ALL. Treatment included multidrug chemotherapy and prophylactic intrathecal injections of methotrexate and prednisolone. Low-grade MEC of the left parotid gland was diagnosed at the age of 7 years, only 1 year after completing treatment. Local lymph nodes were not metastatic, and course was favorable 8 years after complete surgical excision. This case report is remarkable for the early diagnosis of second cancer, only 4 years after diagnosis of ALL, and its occurrence in parotid gland without previous head and neck irradiation. It highlights the need for concern about second cancers of the parotid gland in children treated for ALL.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed2005

Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952.

BACKGROUND: Patients with Down syndrome (DS) and standard risk (SR) acute lymphoblastic leukemia (ALL-DS) are reported to have inferior event free (EFS) and overall survival (OS) compared to patients without DS (ALL-NDS). PROCEDURE: We compared the prevalence of favorable and unfavorable clinical and biologic features, toxicity and outcome within the ALL-DS and ALL-NDS cohorts of 2,174 eligible patients with SR-ALL enrolled on CCG-1952. RESULTS: Fifty-nine patients (3%) had ALL-DS. DS patients were less likely to have either favorable (hyperdiploidy, triple trisomy of chromosomes 4, 10, and 17, TEL-AML1 rearrangement) or unfavorable (T-cell ALL, hypodiploidy, adverse translocations) biologic features. Toxicity occurred significantly more often and number of days hospitalized was significantly greater in ALL-DS than in ALL-NDS. ALL-DS patients had an inferior 4-year EFS compared to the NDS cohort. However, EFS was equivalent when the comparison excluded ALL-NDS with favorable biologic features. OS was significantly inferior for ALL-DS. CONCLUSIONS: The absence of favorable biologic features within ALL-DS contributes to the difference in EFS previously observed between DS and NDS SR-ALL cohorts.

Antineoplastic Combined Chemotherapy Protocols↗